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ABSTRAK 
 
PEMBANGUNAN TINDAK BALAS BERANTAI POLIMERASE BEKU 
KERING UNTUK PENGENALPASTIAN BERTERUSAN POLIMORFISME 
SATU NUKLEOTIDA BAGI GEN CYP2B6 DAN GEN OPRM1 
 
 
Penggunaan heroin secara haram dan HIV adalah dua ancaman utama yang dihadapi 
oleh Malaysia dan juga negara lain. Majlis AIDS Malaysia melaporkan jumlah 
keseluruhan kes HIV di Malaysia pada Jun 2009 adalah sebanyak 86,127 kes dan 
jumlah ini telah meningkat sebanyak 3 kali ganda jika dibandingkan dari tahun 1986. 
Kadar peningkatan kes HIV dijangka akan menyebabkan 24 juta rakyat Malaysia 
dijangkiti dengan HIV/AIDS pada tahun 2020 di mana jumlah keseluruhan populasi 
pada ketika itu dijangka sebanyak 40 juta. Punca utama jangkitan HIV di Malaysia 
dan juga Asia Timur Selatan adalah disebabkan oleh perkongsian jarum suntikan 
tercemar di kalangan penagih dadah. Statistik menunjukkan 71% kes HIV di 
Malaysia adalah kerana perkongsian jarum oleh penagih dadah. Metadon dan 
antiretroviral digunakan secara besar-besaran untuk membasmi masalah ini. Kedua-
dua dadah ini dipengaruhi oleh CYP2B6 manakala reseptor opiat µ turut 
mempengaruhi metadon. Kedua-duanya adalah polymorfisme dari segi genetik. 
Objektif kami adalah untuk menghasilkan “multiplexed allele- specific PCR” untuk 
deteksi/pengesanan polymorfisme ini dan mengoptimumkan dengan terapi metadon 
dan antiretroviral di samping menghasilkan kaedah PCR beku kering supaya 
memudahkan penggunaan rutin dalam makmal diagnostik. Bahagian gen reseptor 
opiat µ (OPRM1) dan CYP2B6 digandakan dahulu sebelum digunakan sebagai 
xi
template bagi PCR spesifik alel kedua. Tiga “single nucleotide polymorphism” 
(SNPs) dari CYP2B6 dan tiga SNPs dari OPRM1 disasarkan. Satu set daripada 
kaedah PCR pertama (bahagian gen masing-masing yang merangkumi SNPs sasaran) 
dan tiga set daripada PCR kedua (masing-masing menggandakan dua SNPs sasaran) 
akhirnya dihasilkan. SNPs daripada OPRM1 dan CYP2B6 berjaya digandakan 
dengan menggunakan kaedah yang telah dibangunkan. Hasil keputusan disahkan 
dengan menggunakan jujukan DNA secara langsung. Kawalan positif untuk kesemua 
mutasi dihasilkan dengan menggunakan kaedah “site-directed mutagenesis”. 
Kawalan positif ini divalidasi dengan menggunakan jujukan DNA secara langsung. 
Kawalan positif diuji terhadap kaedah PCR yang dibangunkan menunjukkan hasil 
yang tepat. Kaedah “nested allele-specific” PCR berjaya dihasilkan untuk deteksi 
SNP daripada OPRM1 dan CYP2B6. Kaedah PCR yang dihasilkan seterusnya 
dibeku kering dengan menggunakan enzim stabilizer yang bersesuaian. Kaedah PCR 
beku kering didapati sensitif mengesan sehingga 5 ng DNA yang terdapat dalam 
sampel. Ujian kestabilan pantas menunjukkan PCR beku kering adalah stabil 
sehingga setahun pada suhu 4oC. Kaedah ini akan digunakan secara rutin dalam 
makamal diagnostic untuk mengoptimumkan terapi metadon dan antiretroviral bagi 
engurangkan risiko penularan HIV. 
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ABSTRACT 
DEVELOPMENT OF THERMOSTABILIZED PCR METHOD FOR 
THE SIMULTANEOUS DETECTION OF SNPS OF CYP2B6 AND OPRM1 
GENES 
 
Illicit heroin use and HIV are double threats faced by Malaysia and some parts of the 
world. Malaysian AIDS Council reported the total number of HIV cases in Malaysia to 
be 86,127 by June2009, was merely 3 in the year 1986. With the rate of increase in HIV 
it is estimated that about 24 million Malaysians will be infected or affected by 
HIV/AIDS by the year 2020 where the total population is estimated to be 40 million. In 
Malaysia and parts of South East Asia, the prime vehicle for HIV transmission is the 
sharing of contaminated injection needles by drug users. Statistics shows that 71% of 
the HIV cases in Malaysia are due to sharing of needles/syringe by the Injecting drug 
users. To combat the threats, methadone and antiretrovirals are widely used. These 
drugs are influenced by CYP2B6 and for methadone, µ Opiate-receptor is also involved.  
Both are genetically polymorphic. Our objective was to develop a multiplexed allele-
specific PCR for the simultaneous detection of these polymorphisms to optimize 
therapies with methadone and antiretrovirals and to freeze dry the PCR method so as to 
make it feasible for routine diagnostic laboratory use.  Regions from µ Opiate-receptor 
parallel allele-specific second PCR. Three single nucleotide polymorphisms (SNPs) 
from CYP2B6, and three SNPs from OPRM1were targeted.  One set of first PCR 
method (regions in the respective gene covering the targeted SNPs) and three sets of 
xiii
gene (OPRM1) and CYP2B6 were first amplified and then used as templates for 
second PCR (each amplifying two targeted SNPs) were finally devised. The targeted 
SNP’s from OPRM1 and CYP2B6 were successfully amplified using the developed 
methods. The results were confirmed by direct DNA sequencing. Positive controls for 
all these mutations were devised using site-directed mutagenesis approach. These 
positive controls were validated by direct DNA sequencing. These controls tested 
against the developed PCR method showed accurate results. A nested allele-specific 
PCR method was successfully developed for the simultaneous detection of SNP’s from 
OPRM1 and CYP2B6.  The PCR method hence developed was freeze dried by using 
suitable enzyme stabilizer. The freeze dried PCR method was found to be sensitive 
enough to detect up to 5 ng of DNA present in the sample. Accelerated stability study 
showed the freeze dried PCR stable up to 1 year at 4°C. This method will be used in 
routine diagnostic laboratories to optimize therapies with methadone and antiretrovirals 
to reduce risks for HIV transmission.  
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Chapter 1 
General Introduction 
1.1   Introduction 
Spread of HIV/AIDS has been threatening the fundaments of Malaysian society along 
with other parts of Asia. Malaysian AIDS Council reports total number of HIV cases in 
Malaysia to be 86,127 by June2009, which was merely 3 in the year 1986 (MAC, 
2008). With the rate of increase in HIV it is estimated that about 24 millions Malaysians 
will be infected or affected by HIV/AIDS by the year 2020 where the total population is 
estimated to be 40 million (MAC, 2008). Demography may change because of the 
preponderance of the disease among specific groups such as the young males, the 
gender ratio as of 2008 is 4 men to every women. In Malaysia and parts of South East 
Asia, the prime vehicle for HIV transmission is the sharing of contaminated injection 
needles by drug users. Statistics shows that 71% of the HIV cases in Malaysia are due 
to sharing of needles/syringe by the Injecting drug users (MAC, 2008). Thus, the dual 
threat of illicit drug use and HIV is increasing in Malaysia. To encounter the problem 
Malaysian government introduced Methadone Maintenance Therapy (MMT) in the year 
2006, with the objective of removing the need for the sharing of contaminated needles 
by injecting drug users as well as to reduce overall harms associated with illicit drug use 
(Nasir et al, 2010). 
 
MMT is the most effective management of opiate dependence. It have been used world 
wide to reduces illicit opiate use along with the objectives to improves personal and 
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social functioning and also reduces drug related crimes. Most importantly it controls 
HIV spread through the sharing of injection equipment among drug users (Nasir 
Mohamad, 2010). Methadone is generally given as a racemic mixture. Although, the 
activity of Methadone is attributed to the R-enantiomer, the S-enantiomer may be 
important in cardiotoxicity and undergoes stereo-selective metabolism with 
CYP2B6(Totah et al., 2008). Patient on MMT might also be receiving drugs from 
Highly Active Antiretroviral Therapy (HAART) for AIDS. This can lead to potential 
Drug-drug interaction as antiretroviral agents used in HAART like Efavirenz, 
Nevarapine are metabolized by CYP2B6 (Haas et al., 2009).  
 
1.2   Pharmacogenetics  
Various factors like age, sex, ethnicity, body weight, dietary habits, concomitant drug 
use and exposure to chemicals are responsible for varied drug response (Brazell et al., 
2002). Genetic variation is recognized as one of the factors influencing the drug 
response this research area is defined as Pharmacogenetics (Wolf et al., 2000) . Though 
defined in 2000, there were cases where researchers have realized the potential 
influence of enzyme variation in some adverse drug events (Meyer, 2000).  
 
Koo and Lee, define Pharmacogenetics as the study of heredity and response to drugs.  
The aim of Pharmacogenetics is based on genetic tests provide aid for giving right 
medicine with right dose which attempts to achieve maximum efficacy and minimum 
toxicity (Koo and Lee, 2006). ADR is an important consequence of drug therapy, 6.7% 
patients in US develop Adverse Drug Reactions (ADRs) out of which 0.32% develop 
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fatal reactions (Lazarou et al., 1998). Similarly, 11.5%, 13.0% and 16.0% of hospital 
admission are due to for ADRs in Norway, France and UK respectively (WHO, 2002). 
It may be appropriate to adjust drug doses in accordance to the results of genetic tests. 
This facility of tailoring medicines will be effective to prevent ADRs and also be 
helpful in reducing the direct costs of therapy and indirect cost of hospitalization. The 
information from Pharmacogenetic tests can also be used in drug development and 
design targeted for specific population (Brazell et al., 2002). It can also be used for 
preventive purposes, by identifying the gene/ genetic variation causing certain ADRs 
that can be then prevented using Pharmacogenetics. Prescription of drugs with narrow 
therapeutic index and metabolic polymorphism are the most important benefits with 
Pharmacogenetics (Wolf et al., 2000). During drug development knowledge of 
Pharmacogenetic variations helps to avoid unnecessary costs of adverse drug events due 
to genetic traits (Wolf et al., 2000).  
 
Pharmacogenetics has progressed rapidly in the past years, after the term was coined in 
1959 by Vogel. After the publication of the guidelines by FDA for submission of 
Pharmacogenomics data, pharmacogenomics have formally entered the field of 
healthcare (FDA, 2005). About 10% of the FDA approved drug labels contain 
pharmacogenetic information. The genetic biomarkers are intended to play a role in 
identify the Responders and Non-Responders, to avoid toxicity and to adjust the dose to 
ensure efficacy and safety. The genetic biomarkers are classified according to their 
specific use like clinical response and differentiation; risk identification; dose selection 
guidance; susceptibility, resistance and differential disease diagnosis; and polymorphic 
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drug targets (FDA). There are certain biomarkers classified as Valid Biomarkers by the 
FDA and are required in the labels of relevant drugs. CCR-5, CYP2C19 variants, 
CYP2C9 variants, CYP2D6 variants, NAT2 variants are some of the selected 
biomarkers and are indicated to be included in drug labels. A typical label example as 
required by the FDA is,  
 
CYP2C9 Variants  CYP2C9 Variants PM and EM genotypes 
and drug exposure; “Patients who are 
known or suspected to be P450 2C9 poor 
metabolizers based on a previous history 
should be administered celecoxib with 
caution as they may have abnormally high 
plasma levels due to reduced metabolic 
clearance.” 
Celecoxib 
  The information on CYP2C9 variant as appeared on Celecoxib labels (FDA, 2010).        
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1.3   CYP Family 
Cytochrome P450 are of heme containing enzymes responsible for phase-I metabolism 
of drugs and other exogenous and endogenous compounds. They get this name due to 
their characteristics optical property of absorbing light at 450 nm. This distinctive 
property is due to the presence of reduced heme, which when bound to drugs can bind 
with cabon monoxide to form complexes possessing this typical characteristic (Omura, 
1999). Factors effecting variation on CYP450 activity include 1. Genetic 
polymorphisms, 2. Environmental factors, 3. Physiological status and 4. Disease state. 
The variations on CYP enzymes are responsible for variable response to drugs leading 
to adverse reaction or lack of efficacy (Amal Al Omari, 2007, Omura, 1999). 
 
CYP enzymes are classified into families and subfamilies according to the homology 
they have with each other. This standard nomenclature system was introduced in 1996. 
Forty percent homology is assigned as a family represented by a number, 55% 
homology is assigned a subfamily represented with a letter and the individual enzymes 
are again designated an individual number. For most of the enzymes the “wild-type” is 
designated *1, and other alleles with different numbers with “*” (Nelson et al., 1996). 
There are more than 57 active human CYP450 genes and 58 pesudogenes. The majority 
are polymorphic(Rodriguez-Antona and Ingelman-Sundberg, 2006).  
 
Despite the presence of the large number of CYPs, only CYP1, CYP2, and CYP3 
families have major roles in drug metabolism. Other CYPs are involved in the 
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metabolism of endogenous compounds. In general only about 10 CYP enzymes are 
involved in drug metabolism. 
 
 
Table 1.1:   Major enzymes contributing drug metabolism 
                 
 Enzyme Estimated contribution to drug metabolism 
(% of drug metabolized by the enzyme) 
CYP1A1/2 3 
CYP2A6 3 
CYP2B6 3 
CYP2C8/9 12 
CYP2C19 8 
CYP2D6 19 
CYP2E1 1 
CYP3A4/5 51 
 
Adapted from (Amal Al Omari, 2007). 
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  Out of all the CYPs, CYP2 family is the largest family involved in the metabolism of 
drugs in mammals. The family is subdivided into CYP2A, CYP2B, CYP2C, CYP2D 
and CYP2E. CYP2B6 is a member of the CYP2B subfamily. 
 
1.3.1   CYP2B6 
CYP2B6 is found in small quantities of 3-5% in liver cells; its presence is very low in 
extrahepatic tissues like the brain, lungs, intestine and the  kidneys (Wang and 
Tompkins, 2008). Though, earlier thought to be not clinically important, recent studies 
showed that CYP2B6 is involved in the metabolism of many drugs; ranging from 
therapeutically important drugs to recreational drugs. Moreover, it is also involved in 
the metabolism of endogenous chemicals and  pesticides and it is also involved in the 
activation of procarcinogens (Ekins and Wrighton, 1999). Some of the common 
compounds involving CYP2B6 in their metabolism include, chemotherapeutics like 
cyclophospamide, ifosfamide, tamoxifen; anti retrovirals like, efavirenz, nevarapaine; 
antidepressants like, bupropion; anti epileptic like mephobarbital, valporic acid; 
anesthetics like, propofol, ketamine; opioids like, methadone, pethidine; psychotropic 
like, diazepam, midazolam; steroids like, estrogen and testosterone and procarcinogens 
like; alfatoxins and nitrosamines are activated by CYP2B6 (Hesse et al., 2000) (Chang 
et al., 1998) (Chung et al.) (Xie et al., 2003).       
 
Apart from metabolizing many drugs, CYP2B6 generally also shares substrates with 
CYP3A4. In parallel with the increasing role of CYP2B6 in the metabolism of 
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xenobiotics, there is an increase in the chances of interactions mediated by CYP2B6. 
Bupropion is considered to be a probe drug for the study of CYP2B6 activity. Several, 
studies however reveal that other CYP enzymes are also involved in the metabolism of 
bupropion. Production of a specific metabolite and differences in affinity are the 
characteristic feature of CYP2B6 metabolism of this drug compared with other CYPs 
like CYP3A4, CYP2C9 and CYP2C19. Recent studies show that CYP2B6 selectively 
catalyzes the hydroxylation of S-bupropion (Hesse et al., 2004). Generally, brupopion is 
given as a racemic mixture of R and S for therapeutic purposes. This characteristic of 
catalyzing the hydroxylation of S-bupropion by CYP2B6 is utilized for using brupopion 
as a probe drug by identifying the specific metabolite S, S-hydroxybupropion (Joy et 
al.). This stereo-selective property of CYP2B6 is also seen with methadone (Totah et 
al., 2008).  
 
Methadone is a synthetic opioid used in Methadone Maintenance Therapy for opiate 
users. It has been used for the treatment of opiate dependence for more than 30 years. 
Methadone binds to the opiate receptor, to prevent opiate withdrawals and to enable 
drug users to live a normal life.(Nasir et al, 2010). 
 
Methadone is given as a racemic mixture. Only the R-methadone binds to the mu-opiate 
receptors to exert its opiate effects. S-methadone doesn’t exert similar effect but inhibits 
the cardiac potassium channel. S-methadone is responsible for the cardiac toxicity of 
methadone that even sometimes leads to sudden death.    
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 1.3.1.1   SNPs in CYP2B6 
Unlike well established CYP enzymes like CYP2D6 or CYP2C19, studies on the 
polymorphisms of CYP2B6 have only recently been studied. In CYP2B6 SNPs are 
present in both the coding and non-coding regions. SNPs in the coding region i.e. in 
nine codons represent nonsynonymous and silent mutations. 
 
There are many SNPs in the non coding region as well. SNPs in the regulators or 
introns also influence the gene expression. Since, CYP2B6 is highly inducible this facts 
leads it to be a potential area for studying the SNPs in these regions. 
 
 
Table 1.2:   SNPs at both coding and non coding region of CYP2B6 and their 
effects  
Allele  Nucleotide changes  Enzyme activity  References  
CYP2B6*1B  -2320T>C  N/A Lamba et al., 
2003  
CYP2B6*1C  -2320T>C; 
14593C>G; 
15582C>T  
N/A Lamba et al., 
2003  
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CYP2B6*1E  -1578C>T; -757C>T  N/A Lamba et al., 
2003  
CYP2B6*1F  -1224A>G  N/A Lamba et al., 
2003  
CYP2B6*1G  -750T>C  N/A Lamba et al., 
2003  
CYP2B6*1H  -2320T>C; -750T>C  N/A Hesse et al., 2004  
CYP2B6*1J  -2320T>C; -
1778A>G; -
1186C>G; -750T>C  
N/A Hesse et al., 2004  
CYP2B6*1K  -1972C>T; -
1578C>T; -750T>C  
N/A Hesse et al., 2004  
CYP2B6*2B  64C>T; 12740G>C  N/A Lamba et al., 
2003  
CYP2B6*4B  -2320T>C; -
1778A>G; -
1186C>G; -750T>C; 
18053A>G  
N/A Hesse et al., 2004  
CYP2B6*4C  18053A>G; 
12917A>T  
N/A Jacob et al., 2004  
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CYP2B6*5B  -2320T>C; -
750T>C; 25505C>T  
N/A Hesse et al., 2004  
CYP2B6*6B  -1456T>C; -
750T>C; 
15631G>T;18053A>
G  
N/A Hesse et al., 2004  
CYP2B6*7B  -1456 T>C; -
750T>C; 
15631G>T;18053A>
G; 25505C>T  
N/A Hesse et al., 2004  
CYP2B6*8  13072A>G  Decreased 
expression of the 
enzyme 
Lamba et al., 
2003 Lang et al., 
2004  
CYP2B6*9  -1456T>C; 
15631G>T; 
21563C>T  
N/A Lamba et al., 
2003  
CYP2B6*10  62A>T; 64C>T; 
12740G>C  
N/A Lang et al., 2004  
CYP2B6*11A  136A>G  Decreased activity 
of enzyme 
Lang et al., 2004  
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 1.3.1.2   Clinical implications of CYP2B6 polymorphism 
As stated, CYP2B6 is involved in metabolism of many drugs including cyclosporine, 
efavirenz, nevarapine and many other important drugs. Altered expression, enzyme 
inhibition or polymorphisms of CYP2B6 have mainly been studied with cyclosporine 
and efavirenz (Xie et al., 2003)(Ramachandran et al., 2009). Both these drugs have 
narrow therapeutic indices and show large interindividual variation in plasma drug 
concentration (Penzak et al., 2007).  
 
The antiretroviral drug efavirenz is a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) which is one of the drugs given in combination for HIV infected individuals. 
Efavirenz is shown to have high plasma concentration variation. It has been reported 
that higher plasma concentrations of efavirenz causes symptoms like difficulty in 
sleeping, dizziness, depression responsible for discontinuation of the drug and treatment 
failures.  Studies using human liver microsomes and recombinant CYPs by Ward et al. 
showed that CYP2B6  was involved in the metabolism of efavirenz; 8-hydroxy-
efavirenz and 8,14-dihyrroxy-efavirenz were identified as primary metabolites. Further 
pharmacogenetic studies showed that CYP2B6*6, specifically SNP 516 G>T was 
associated with elevated plasma concentrations.(Ramachandran et al., 2009). 
Subsequently, population genotyping was used as a tool for efavirenz dose optimizing. 
CYP2B6*6 is common in west African and Papua New Guinean populations, countries 
with serious problems with HIV (Mehlotra et al., 2007) (Penzak et al., 2007). 
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Identification of “slow metabolizers’ was helpful for dose optimization and to decrease 
adverse events. A similar study in Japan used to decreases efavirenz dose by 33% to 
66% but the plasma concentration  was maintained leading to better therapeutic 
outcomes (Tsuchiya et al., 2004).  
 
1.4   Opioid receptors  
Opioids have been used by human since ancient times and they were cultivated in 
Mesopotamia as early as 3400 BC. It has been in use for thousands of years for pain 
reliving. The first scientific work with opioids dated back to 1973, when a graduate 
student used radioactive morphine to locate the site of action for morphine (Trescot et 
al., 2008). It was observed that morphine was specifically attached to a specific area 
termed “morphine receptors”. Though this phenomenon was observed in 1973, opioid 
receptor research was only started in the fifties when clinical interaction studies were 
carried out. By the sixties there were already proposals for the structure and mechanism 
of opioid receptors (Chahl, 1996). 
 
The first key on the biological receptors was depicted by Lee on using snake toxin and 
its effect on nicotine acetylcholine receptors. Subsequently studies showed the presence 
of opioid receptors, the presence of endogenous opioids and by 1976 three different 
opioid receptors were proposed that were further subdivided (Wang et al., 1994).  
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Morphine is agonist to mu-receptors. The mu receptor has subtypes that include mu1 
and mu2. Mu1 mediates analgesia and euphoria whereas mu2 is associated with 
respiratory depression and sedation. On the other hand, Kappa receptor has 
Ketocyclazocine as its agonist. Kappa receptor mediates spinal analgesia, sedation, 
dyspenea and dependence. For Delta receptor its agonist is delta-alanine-delta-leucine-
enkephalin. They are responsible for psychometric and dysphoric effect. Sigma 
receptors are no more considered as opioid receptors and are classified under targets for 
Phencyclidine and analogues (Trescot et al., 2008). 
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Table 1.3:   Different opioids and their effect at different receptors       
 
Adapted from (Trescot et al., 2008).  
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1.4.1   Mu-opioid receptors 
Mu opioid receptors are so named because they have morphine as agonists. They are 
primarily found in the brain stem and medial thalamus. They are responsible for 
supraspinal analgesia, euphoria, sedation, respiratory depression, decrease 
gastrointestinal motility and physical dependence. There are two subtypes of mu-
receptors mu1 and mu2. Mu1 receptors are related to analgesia, euphoria and serenity. 
Mu2 receptors are related to respiratory depression, pruritus, prolactin release, 
dependence, anorexia and sedation. 
 
Since, the mu opioid receptor is a member of G-protein coupled receptors (GPCRs) its 
regulation involves different processes like desensitization, internalization, 
resensitization and down regulation. GPCR kinases (GRKs) and β arrestins play major 
role in these processes. When GPCRs are stimulated by agonists, GRKs initiate receptor 
phosphorylation. This leads to recruitment of β arrestins which uncouples the receptor 
and G protein thus preventing further signaling. This is termed as desensitization. β 
arrestins also facilitate the internalization of inactivated receptors with possible 
promotion of receptor recycling to plasma membrane or downregulation by receptor 
degradation. This process of signaling holds true for morphine and is different for 
different opioids. Agonists like morphine, etorphine, methadone and fentanyl can 
activate the receptors with similar efficacy but they differ in their ability to promote 
desensitization and internalization. Morphine and heroin do not promote receptor 
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endocytosis but other agonists like methadone, etorphine and fentanyl promotes the 
endocytosis (Wang et al., 1994).  
 
Adapted from: (Chahl, 1996) 
Fig 1.1:   Opioids action via receptors  
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1.4.1.1   SNPs in mu-receptor gene (OPRM1) 
Mu-opioid receptor gene is located on chromosome 6 at position q25.2 and is composed 
of 4 exons (Wang et al., 1994). There have been studies on SNPs of µ-opioid receptor 
and its association with opiate addiction and alcohol dependence. SNPs at OPRM1 are 
present at 5’ UTR region, exons, introns, and 3’ UTR regions. Below is the list of the 
SNPs at OPRM1 genetic loci with their corresponding amino acid changes.  
 
Table 1.4:   SNPs at OPRM1 gene 
Position Location in the gene  Amino Acid change 
-1045 A/G 5’UTR - 
-995 C/A 5’UTR - 
-692 G/C 5’UTR - 
-554 G/A 5’UTR - 
-488 G/T 5’UTR - 
-245 A/C 5’UTR - 
-236 A/G 5’UTR - 
-172 G/T 5’UTR - 
-133 C/T 5’UTR - 
-111C/T 5’UTR - 
-54 G/T 5’UTR - 
-38 C/A 5’UTR - 
 18  
17 C/T  Exon 1  Ala/Val 
24 G/A Exon 1 Synonymous 
118 A/G Exon 1 Asn/Asp 
440 C/G Exon 2 Ser/Cys 
454 A/G Exon 2 Asn/Asp 
IVS2+31 G/A Intron 2 - 
IVS2+106 T/C Intron 2 - 
IVS2+397 T/A Intron 2 - 
IVS2+438 G/A Intron 2 - 
IVS2+480 T/C Intron 2 - 
IVS2+534 C/T Intron 2 - 
IVS2+691 C/G Intron 2 - 
779 G/A Exon 3 Arg/His 
794 G/A Exon 3 Arg/His 
802 T/C Exon 3 Ser/Pro 
820 G/A Exon 3 Asp/Asn 
942 G/A Exon 3 Synonymous 
IVS3+37 A/C Intron 3 - 
401 G/C 3’UTR - 
 
Table modified from (Xin and Wang, 2002). 
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1.4.1.2   Clinical implication of OPRM1 polymorphism 
As listed above there are many SNPs at OPRM1 and many studies have been carried 
out on these SNPs. However, most of the studies focus on the most prevalent SNP 
which  is a nucleotide substitution at position 118 (A118G) (Bond et al., 1998) (Kim et 
al., 2009) (Coller JK, 2009). This SNP predicts an amino acid change at a putative N-
glycosylation site (Bond et al., 1998). This variant has also been shown to be of 
physiogenetically (genetically based difference in physiology) and pharmacogenetically 
important. The frequency of this variant varies widely across populations, occurring at 
less than 2% in some populations (Bond et al., 1998) and up to 50% in other 
populations (Gelernter et al., 1999). 
 
Bond et al (1998) also studied the binding of β-endorphin on the A118G variant and its 
prototype. The cellular activities of µ-opioid receptors were also studied, and the 
outcome showed that there is a similarity in the activity of the prototype and the variant 
receptor. on the other hand, β-endorphin showed a 3-fold greater potency in the 
activation of K+ current in A118G variant compared to the prototype. Persons who 
carry this variant gene may show altered function of the µ-opioid receptor. 
 
Other studies have suggested that this polymorphism (A118G) may also result in altered 
pharmacogenetic response; with individuals carrying the 118G allele having different 
physiological and analgesic response to morphine (Lotsch et al., 2002). Also, 
heterozygous and homozygous mutant genotype of this polymorphism have been 
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